Ecoceuticum

The ecoceuticum concept has its intellectual origin in basic ecological thinking, observing that humans – especially children – and all animals have an irresistible urge for eating soil. It appears they are craving for soil substances with properties as in the patented deconstructed soil invention, as described here.

 

The ecoceuticum consists of natural substances in soil which humans and animals have been deprived of in modern societies. These naturally occurring biopolymers restore microbial balance in the gut. The ecoceuticum regulates ecological mechanisms which control species interactions in complex microbial communities. It is fundamentally different from probiotics, prebiotics, postbiotics/quorum-sensing molecules, parabiotics, and fecal transplantation.

 

The ecoceuticum stops inflammation in gut epithelia and leakage of oxygen into the gut. It also facilitates sharing of energy among all species in microbial ecosystems by rapid inter-species electron shuttling. It supports the great variety of species found in the microbial community of the human colon. Species favored are vulnerable strict anaerobic gut bacteria (often regarded as beneficial), whereas potentially dangerous species are disfavored and kept at bay – without killing them. A functioning gut microbiota is imperative to stay healthy.

A concept for the future

There are multiple possible applications and developments of the ecoceuticum concept. By counteracting the dangerous imbalance in the gut microbiota – a root cause of dysbiosis – the ecoceuticum concept may be highly relevant to combat the multiple lifestyle diseases and other conditions caused by gut microbiota dysbiosis. Since a healthy gut microbiota is a prerequisite for good health, developments of the ecoceuticum may also offer protection against infectious diseases and epidemics.

 

The outcome of certain pharmacological disease treatments also depends on a healthy gut microbiota. Possible developments of the concept in this direction may be ambitious and require significant effort and patient financing, but still justified because of the magnitude of the potential health implications. But ecoceuticum products to support the gut microbiota combined with other treatment may be done at a fraction of the cost and time required for pharmaceutical development.

 

The ecoceuticum may have a potential in enhancing the therapeutic effect of immunotherapy. The 100% subsidiary EderaGen Pharma was established in early 2026 as a vehicle to verify such possible favorable effects of the ecoceuticum, e.g. on the therapeutic efficacy of cancer antibodies, as described here.